drugset / Trial / NCT03611556
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Timeline
- Start
- 2018-06-21
- Primary completion
- 2022-07-22
- Completion
- 2022-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oleclumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Oleclumab | Monoclonal antibody | 3000 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |